{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sciatica-lumbar-radiculopathy/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"99267823-da67-5e95-a5e6-61d268a8dbee","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ec1950fd-bf0f-4690-8202-d2343603d2ff --><h2>Changes</h2><!-- end field ec1950fd-bf0f-4690-8202-d2343603d2ff -->","summary":null,"htmlStringContent":"<!-- begin item 850e903c-34d8-4802-a709-7ff34dd721d7 --><!-- begin field 9f524753-6ae5-49fa-bc6f-6f52c81e5f52 --><p><strong>December 2020 </strong>— minor update. Recommendations on offering neuropathic drugs at follow-up, and advising people with sciatica when to seek follow-up have been clarified. </p><p><strong>September 2020 </strong>— minor update. The management recommendations have been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Low back pain and sciatica in over 16s: assessment and management</em>. A recommendation that digital rectal examination does not need to be performed in primary care to assess for anal tone, but can be considered, has been added to the section on red flag symptoms and signs in line with the National Back Pain Clinical Network document <em>Early recognition of cauda equina syndrome: a framework for assessment and referral for primary care / MSKinterface</em>. </p><p><strong>March 2018</strong> — minor update. New symptoms added to <a class=\"topic-reference internal-reference\" href=\"/topics/sciatica-lumbar-radiculopathy/diagnosis/red-flag-symptoms-signs/\">Red flag symptoms and signs</a> to bring topic in line with current evidence.</p><p><strong>January to March 2017 </strong>— reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 9f524753-6ae5-49fa-bc6f-6f52c81e5f52 --><!-- end item 850e903c-34d8-4802-a709-7ff34dd721d7 -->","topic":{"id":"ad9c3284-4348-51f2-bbdc-8dd5e93fe217","topicId":"1d568c4f-007a-4c46-a757-366c49d1468c","topicName":"Sciatica (lumbar radiculopathy)","slug":"sciatica-lumbar-radiculopathy","lastRevised":"Last revised in December 2020","chapters":[{"id":"61580b78-914f-553d-929e-e7509b48b968","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"03bfe5a6-4c9c-5d2b-be5c-806c18081f98","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d07cbef-097c-52e8-aca3-605dda07ba5c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"99267823-da67-5e95-a5e6-61d268a8dbee","slug":"changes","fullItemName":"Changes"},{"id":"3a12122a-5c0b-50d0-b642-4fd721314790","slug":"update","fullItemName":"Update"}]},{"id":"16ad9db1-91b2-5511-af84-29bf3d72c0db","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"593dd0df-0f08-58e4-9a56-17d0f28eac8d","slug":"goals","fullItemName":"Goals"},{"id":"10dc73f3-1cf6-5546-909c-0d0039d9a087","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6658a487-9512-53ce-8e66-963bcfa0bb3c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"bfd5b8dc-bc5a-514b-a266-a53aea0f6779","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"554dad69-7c4c-5339-a038-4ab65628970c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25ca6d9e-48ce-5cac-b7dc-e580001be20a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"607a1844-8645-5c21-a869-86f49c6bf789","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"490b000c-d3ca-5d4d-a2aa-1adfb7547486","slug":"definition","fullItemName":"Definition"},{"id":"505e1092-1f2c-5bfe-b7ff-2a3ca2cf7d5b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ec4ca159-0997-5e80-be14-fb47995f2de3","slug":"causes","fullItemName":"Causes"},{"id":"c1ffa2e3-7d1d-5a6a-a3d9-fa121b2a08bf","slug":"complications","fullItemName":"Complications"},{"id":"39ddcd8f-e6a0-5ddf-8dfd-4de3a5b0cc68","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"60da5afb-6001-5b1a-816f-976ef7938d2e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c0bd5b01-54b9-5255-a0d7-4b04c6c7598e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"642adff2-0ad2-52c8-84f5-7b061aac14c3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5a48f08-6adb-598e-8924-1fc781c6fa4a","slug":"red-flag-symptoms-signs","fullItemName":"Red flag symptoms and signs"},{"id":"a9a096f8-b0c7-51aa-9b5b-840751fc68e6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"cec66668-8653-5edf-993e-156446653dd4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b748ac01-27d7-553a-ba93-36cacaba6ac8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1465a10e-5334-58ab-b479-92a27d919e9f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9082b834-10ed-5550-b92d-408158591697","slug":"nonsteroidal-anti-inflammatory-drugs-nsaids","fullItemName":"Nonsteroidal anti-inflammatory drugs (NSAIDs)"}]},{"id":"e1ad20bd-1585-5c3e-8710-d8dec0f2d459","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d2afd88-9cf1-56a7-86c1-7483e0083d8d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"803c0f7d-e023-5c9c-a165-67628dae9f7f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"37ec2adc-61cd-5cf3-bb41-7da4fcf756ea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df22eaa7-884f-57cb-be9e-0cdba2ca3041","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"19a55618-fe91-5e4f-89c1-477123765ac2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b9f4e828-7b1c-5ef7-96d4-39f19abd4d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1cee0a07-ecb6-5d2d-98eb-39e3ed2e940e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d07cbef-097c-52e8-aca3-605dda07ba5c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"28a1846f-1b41-5290-9101-bffda57a5277","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f2f0c34a-5564-43b3-a1a0-314ea89d2773 --><h3>Previous changes</h3><!-- end field f2f0c34a-5564-43b3-a1a0-314ea89d2773 -->","summary":null,"htmlStringContent":"<!-- begin item 0020d48f-8784-4d31-ae08-612993f40c1e --><!-- begin field 7665a4bf-02c2-4998-994b-c60d9793d17b --><p><strong>April 2015 </strong>— minor update. Update to the text to reflect a new law on drugs and impaired driving.</p><p><strong>March 2015 </strong>— reviewed. A literature search was conducted in January 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring and the prescribing information section has been expanded. No major changes to the recommendations have been made.</p><ul><li>CKS is aware of the increasing prominence of a stratified approach to managing back pain depending on the estimated risk of poor prognosis. However, as this is not available in all areas of the UK, it is difficult to universally recommend this approach. </li></ul><p><strong>June 2014 </strong>— minor update. Update to the text to reflect the fact that tramadol has been reclassified to a Schedule 3 controlled drug.</p><p><strong>May 2014 </strong>— minor update. Update to the text to remove the link to morphine prescriptions. This has been replaced with link to a new prescribing information section on strong opioids.</p><p><strong>July 2013 </strong>— minor update. Update to the text to fix the link to the CKS topic on NSAIDs prescribing issues.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011</strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>September 2010 </strong>— the choice of drug treatment for neuropathic pain has been updated in line with the NICE clinical guideline, <em>Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings</em>. Issued in September 2010.</p><p><strong>June 2010 </strong>— minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.</p><p><strong>July to November 2009 </strong>— topic revised. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2008 </strong>— minor update. Summary of product characteristics for Neurontin<sup>® </sup>updated regarding discontinuation of gabapentin, text updated.</p><p><strong>September 2008 </strong>— converted from CKS guidance to CKS topic structure with no important changes to the recommendations.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>March to July 2005 </strong>— reviewed and updated to take account of the 2004 European Guidelines for the management of low back pain. Validated in June 2005 and issued in July 2005.</p><p><strong>March 2004 </strong>— information updated for nurse prescribers.</p><p><strong>June 2003 </strong>— minor update. New advice from the British Heart Foundation on low-dose aspirin and ibuprofen added.</p><p><strong>March 2002 </strong>— updated to incorporate referral advice from the National Institute for Health and Care Excellence. Issued in April 2002.</p><p><strong>August 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>July 1999 </strong>— reviewed, and updated to take account of revised RCGP guidelines for management of acute non-specific low back pain. Validated in October 1999 and issued in January 2000.</p><!-- end field 7665a4bf-02c2-4998-994b-c60d9793d17b --><!-- end item 0020d48f-8784-4d31-ae08-612993f40c1e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}